Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old
- PMID: 34281996
- DOI: 10.1542/peds.2021-052228
Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old
Erratum in
-
Statement of Correction for Robert H. Pantell, Kenneth B. Roberts, William G. Adams, et al. Clinical Practice Guideline: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. Pediatrics. 2021;148(2):e2021052228.Pediatrics. 2021 Nov;148(5):e2021054063. doi: 10.1542/peds.2021-054063. Epub 2021 Oct 29. Pediatrics. 2021. PMID: 34716222 No abstract available.
Abstract
This guideline addresses the evaluation and management of well-appearing, term infants, 8 to 60 days of age, with fever ≥38.0°C. Exclusions are noted. After a commissioned evidence-based review by the Agency for Healthcare Research and Quality, an additional extensive and ongoing review of the literature, and supplemental data from published, peer-reviewed studies provided by active investigators, 21 key action statements were derived. For each key action statement, the quality of evidence and benefit-harm relationship were assessed and graded to determine the strength of recommendations. When appropriate, parents' values and preferences should be incorporated as part of shared decision-making. For diagnostic testing, the committee has attempted to develop numbers needed to test, and for antimicrobial administration, the committee provided numbers needed to treat. Three algorithms summarize the recommendations for infants 8 to 21 days of age, 22 to 28 days of age, and 29 to 60 days of age. The recommendations in this guideline do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
Copyright © 2021 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: Dr Byington is affiliated with BioFire and IDbyDNA. Dr Woods is affiliated with UpToDate. Dr Munoz-Rivas is affiliated with UpToDate, Moderna, and Pfizer; the other authors have indicated they have no potential conflicts of interest to disclose.
Comment in
-
New AAP guidelines for evaluation and treatment of infants 8-60 days old.J Pediatr. 2021 Nov;238:338-342. doi: 10.1016/j.jpeds.2021.08.058. J Pediatr. 2021. PMID: 34702503 No abstract available.
-
Sufficient Blood Culture Volume.Pediatrics. 2022 Jan 1;149(1):e2021055005C. doi: 10.1542/peds.2021-055005C. Pediatrics. 2022. PMID: 34966921 No abstract available.
-
Authors' Response.Pediatrics. 2022 Jan 1;149(1):e2021055005B. doi: 10.1542/peds.2021-055005B. Pediatrics. 2022. PMID: 34966934 No abstract available.
-
Commentary on New Guidelines for the Evaluation and Management of the Febrile Young Infant.Pediatrics. 2022 Jan 1;149(1):e2021055005A. doi: 10.1542/peds.2021-055005A. Pediatrics. 2022. PMID: 34966935 No abstract available.
-
Authors' Response.Pediatrics. 2022 Jan 1;149(1):e2021055005D. doi: 10.1542/peds.2021-055005D. Pediatrics. 2022. PMID: 34966943 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical